<?xml version="1.0" encoding="UTF-8"?>
<ref id="B35-ijms-21-05559">
 <label>35.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Sallard</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Lescure</surname>
    <given-names>F.-X.</given-names>
   </name>
   <name>
    <surname>Yazdanpanah</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Mentre</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Peiffer-Smadja</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>Ader</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Bouadma</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Poissy</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Timsit</surname>
    <given-names>J.-F.</given-names>
   </name>
   <name>
    <surname>Lina</surname>
    <given-names>B.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Type 1 interferons as a potential treatment against COVID-19</article-title>
  <source>Antivir. Res.</source>
  <year>2020</year>
  <volume>178</volume>
  <fpage>104791</fpage>
  <pub-id pub-id-type="doi">10.1016/j.antiviral.2020.104791</pub-id>
  <?supplied-pmid 32275914?>
  <pub-id pub-id-type="pmid">32275914</pub-id>
 </element-citation>
</ref>
